Massachusetts biopharma hotbed shed R&D, manufacturing workers in 24 as new threats now come to the fore
6.0
来源：
FiercePharma
发布时间：
2025-08-27 08:27
摘要：
Massachusetts biopharma sector is grappling with significant challenges, including a 17.1% drop in venture capital funding and a decline in NIH financial support. The state lost approximately 1,100 R&D jobs in 2024, reflecting broader industry trends. Despite these setbacks, new lab and manufacturing spaces are being developed, indicating ongoing investment in the region.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+1.0分
business_impact
0.5分+0.5分
scientific_rigor
1.0分+1.0分
timeliness_innovation
0.5分+0.5分
investment_perspective
2.5分+2.5分
market_value_relevance
1.0分+1.0分
team_institution_background
0.5分+0.5分
technical_barrier_competition
0.0分+0.0分
关键证据
Massachusetts biopharma industry faces funding slowdowns and job cuts.
Venture capital investments in Massachusetts biopharmas decreased by 17.1%.
Massachusetts received 9.3% of NIH funding, but total funding fell 1.4%.
真实性检查
否
AI评分总结
Massachusetts biopharma sector is grappling with significant challenges, including a 17.1% drop in venture capital funding and a decline in NIH financial support. The state lost approximately 1,100 R&D jobs in 2024, reflecting broader industry trends. Despite these setbacks, new lab and manufacturing spaces are being developed, indicating ongoing investment in the region.